WO1998008954A2 - Production d'heme et d'hemoproteines de recombinaison - Google Patents
Production d'heme et d'hemoproteines de recombinaison Download PDFInfo
- Publication number
- WO1998008954A2 WO1998008954A2 PCT/US1997/014165 US9714165W WO9808954A2 WO 1998008954 A2 WO1998008954 A2 WO 1998008954A2 US 9714165 W US9714165 W US 9714165W WO 9808954 A2 WO9808954 A2 WO 9808954A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heme
- host cell
- hema
- ala
- hemoglobin
- Prior art date
Links
- 150000003278 haem Chemical class 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 36
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims abstract description 114
- 101150112623 hemA gene Proteins 0.000 claims abstract description 97
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 91
- 108010054147 Hemoglobins Proteins 0.000 claims description 53
- 102000001554 Hemoglobins Human genes 0.000 claims description 53
- 241000588724 Escherichia coli Species 0.000 claims description 47
- 241000894006 Bacteria Species 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 108010062374 Myoglobin Proteins 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 229930002875 chlorophyll Natural products 0.000 claims description 4
- 235000019804 chlorophyll Nutrition 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- AVBHZKNQGDKVEA-ZTKUHGNGSA-N 3-[(2s,3s,7s,8s)-7,13,17-tris(2-carboxyethyl)-3,8,12,18-tetrakis(carboxymethyl)-3,8-dimethyl-2,7,23,24-tetrahydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3[C@@]([C@H](CCC(O)=O)C(=C4)N=3)(C)CC(O)=O)N2)CCC(O)=O)=C(CCC(O)=O)C(CC(O)=O)=C1C=C1[C@@H](CCC(O)=O)[C@](C)(CC(O)=O)C4=N1 AVBHZKNQGDKVEA-ZTKUHGNGSA-N 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- QFGKGCZCUVIENT-SXMZNAGASA-M f(430) Chemical compound [Ni].C([C@H]1[C@@H](CCC(O)=O)[C@@](C(C[C@H]2N=C3\C(C(CC[C@H]3[C@@H]2CC(O)=O)=O)=C2/[N-]\C([C@H]([C@@H]2CCC(O)=O)CC(O)=O)=C/C([C@H]2CCC(O)=O)=N3)=N1)(CC(N)=O)C)[C@@]13[C@@]2(C)CC(=O)N1 QFGKGCZCUVIENT-SXMZNAGASA-M 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 238000009825 accumulation Methods 0.000 abstract description 16
- 101150114977 lolB gene Proteins 0.000 description 40
- 230000037361 pathway Effects 0.000 description 37
- 230000015572 biosynthetic process Effects 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 28
- 102000004316 Oxidoreductases Human genes 0.000 description 27
- 108090000854 Oxidoreductases Proteins 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 239000012634 fragment Substances 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 17
- 230000004927 fusion Effects 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 230000006698 induction Effects 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 241000191025 Rhodobacter Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 101150066555 lacZ gene Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- MPUUQNGXJSEWTF-BYPYZUCNSA-N (S)-4-amino-5-oxopentanoic acid Chemical compound O=C[C@@H]([NH3+])CCC([O-])=O MPUUQNGXJSEWTF-BYPYZUCNSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 108010014251 Muramidase Proteins 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 108700009124 Transcription Initiation Site Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000037041 intracellular level Effects 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229950003776 protoporphyrin Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012807 shake-flask culturing Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 101710088758 23kDa protein Proteins 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091007187 Reductases Proteins 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 229940059489 heme arginate Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- 108010036302 hemoglobin AS Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000002089 myocardial stunning Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- HUHWZXWWOFSFKF-UHFFFAOYSA-N uroporphyrinogen-III Chemical compound C1C(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(N2)=C(CC(O)=O)C(CCC(=O)O)=C2CC2=C(CCC(O)=O)C(CC(O)=O)=C1N2 HUHWZXWWOFSFKF-UHFFFAOYSA-N 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- -1 25 μg/ml Chemical compound 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 101710187052 Flavohemoprotein Proteins 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000191023 Rhodobacter capsulatus Species 0.000 description 1
- 241000191021 Rhodobacter sp. Species 0.000 description 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010043391 Thalassaemia beta Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229910007339 Zn(OAc)2 Inorganic materials 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000010275 acute porphyria Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 108010053584 alpha-Globins Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- NIUVHXTXUXOFEB-UHFFFAOYSA-J coproporphyrinogen III(4-) Chemical compound C1C(=C(C=2C)CCC([O-])=O)NC=2CC(=C(C=2C)CCC([O-])=O)NC=2CC(N2)=C(CCC([O-])=O)C(C)=C2CC2=C(C)C(CCC([O-])=O)=C1N2 NIUVHXTXUXOFEB-UHFFFAOYSA-J 0.000 description 1
- 101150000386 cpfC gene Proteins 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 101150042363 hemH gene Proteins 0.000 description 1
- 208000033552 hepatic porphyria Diseases 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 101150011498 lad gene Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- QTTNOSKSLATGQB-UHFFFAOYSA-N uroporphyrinogen I Chemical compound C1C(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(N2)=C(CC(O)=O)C(CCC(=O)O)=C2CC2=C(CC(O)=O)C(CCC(O)=O)=C1N2 QTTNOSKSLATGQB-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- This invention generally relates to the production of heme and heme-containing proteins. More specifically, the invention relates to methods of enhancing heme production in host cells capable of expressing heterologous, heme-containing proteins.
- Heme is an iron-containing porphyrin that serves as a prosthetic group in proteins such as hemoglobin, myoglobin and the cytochromes.
- the biochemical pathway for heme biosynthesis is well known. Except for the initial steps in the formation of ⁇ -aminolevulinic acid (ALA), the pathway is fairly well conserved throughout plants, animals and bacteria.
- ALA ⁇ -aminolevulinic acid
- heme b which is also known as protoheme and ferrous protoporphyrin IX
- Heme b serves as an essential cofactor for b-type cytochromes, catalase and peroxidase.
- Biosynthesis of heme b occurs via a complex, branched pathway that involves up to twelve gene products (Fig. 1).
- ALA the committed precursor in the heme b pathway, is formed from the 5-carbon skeleton of glutamate via the C5 pathway.
- Production of ALA in E. coli occurs in three steps: (1) ligation of tRNA (GTR) synthetase, (2) reduction of the resulting GTR to glutamate 1-semialdehyde (GSA) by GTR reductase, and (3) transamination of GSA to ALA by GSA aminotransferase.
- GTR tRNA
- GSA glutamate 1-semialdehyde
- E. coli cells In non-recombinant E. coli cells, accumulation of large pools of heme b pathway intermediates or free heme b is deleterious to the cells. For example, E. coli cells with mutations in the gene encoding hemH (vis A), are impaired in their ability to insert iron into protoporphyrin IX, and accumulate large pools of protoporphyrin IX, which is light sensitive. Because heme b has a propensity to cause oxidative damage to the lipid and protein components of cellular membranes, heme b is normally found associated with proteins in the cell, rather than as free heme,,. The biochemical and/or genetic mechanism by which E. coli and related bacteria regulate expression of the heme b pathway is poorly understood.
- GTR reductases have been described in E. coli. Two GTR reductase activities of different molecular masses (85 kDa and 45 kDa) have been purified (Jahn et al., J. Biol. Chem.. 266:2542-2548 (1991)). The 45 kDa enzyme is the product of hemA and was thought to be a minor enzyme, and that the major GTR reductase is a 23 kDa enzyme encoded by hemM (Ikemi et al., Gene. 121: 127-132 (1992)).
- Intracellular pools of free heme b and heme synthetic pathway intermediates are regulated in E. coli to prevent toxicity.
- E. coli or other cells produce heme or hemoproteins, especially by recombinant DNA methods, such regulation may cause a problem because the limited availability of precursors can limit the amount of heme and or hemoprotein produced. Therefore, a need exists to overcome the normal regulatory mechanism that limits heme production when enhanced heme production is desired.
- the present invention satisfies this need and provides related advantages as well.
- the present invention relates to methods of enhancing the expression of heterologous heme-containing proteins by increasing the amount of endogenous heme available to host cells. Such methods are accomplished by exposing the hosts cells to increased amounts of ALA either by stimulating the production of ALA endogenously or by adding exogenous ALA to the culture medium containing the host cells.
- the methods are accomplished by inserting at least one copy, preferably multiple copies, of the hemA gene into a host cell to stimulate the endogenous production of ALA in the heme biosynthesis pathway.
- ALA can be supplemented directly in a culture of host cells to increase heme production.
- the host cells of the present invention can be prokaryotic or eukaryotic, such as bacteria, yeast, plant, or animal (vertebrate and invertebrate) cells.
- the host cells are bacteria, for example, E.coli.
- E.coli E.coli and certain other bacteria, the increased production of heme, results in the enhanced expression of the heterologous heme-containing protein.
- Heme-containing proteins include, for example, hemoglobin, myoglobin, chlorophyll, siroheme, factor F430 and heme-containing enzymes.
- Such enzymes include, for example, vitamin B12 catalase and nitric oxide synthetase.
- Various hemoglobins are also contemplated, including wild-type human hemoglobin and variants thereof, including mutant human hemoglobins such as rHbl.l.
- the present invention further provides methods for enhancing heme b production in a host cell, particularly in E.coli.
- the methods are accomplished by inserting one or more copies of the hemA gene into the host cell and culturing the transformed host cell to allow production of an enhanced amount of heme b .
- Figure 1 shows, schematically, the pathway for heme synthesis.
- ALA production is boxed. Genes and enzymes relevant to this study are indicated.
- Figure 2 shows the effect of ALA supplementation and rHbl. l production, on heme pools. Cultures contained no IPTG (D) or 300 mM IPTG ( ⁇ ). Each data point represents the average of three independent trials. Experimental variation (standard deviation) is shown by error bars.
- Figure 3 shows the features of DNA fragments used to identify promoters of hemA.
- the start of the hemA coding sequence is indicated by the ATG codon. Arrows mark the transcription initiation sites identified by Verkamp & Chel , J. Bacterio 171 :4728-4735 (1989).
- the triangle below pSGE864 DNA fragment represents the 72bp DNA segment containing the Al transcription start site that was deleted in the PCR amplification.
- Figure 4 shows the effect of ALA concentration on hemA-lacZ expression.
- Cells were grown in 5 ml cultures and assayed as described in Example 1. Data points represent the average of four independent trials.
- the present invention generally relates to the enhanced production of heterologous hemoproteins and heme in host cells.
- the invention is based on the results of the studies described in the Examples below. The results show:
- heme b is a feedback inhibitor of the heme b pathway; (2) overexpression of rHbl .l (a genetically fused version of human hemoglobin) and
- HemA glutamyl tRNA (GTR) reductase
- GTR glutamyl tRNA reductase
- HemA is rate-limiting
- heme b does not repress ALA formation, while ALA formation limits heme b synthesis.
- the present invention is based on the surprising results of the studies. Therefore, in one aspect of the invention, methods of enhancing the expression of a heterologous hemoprotein are provided. Such methods can be accomplished by first exposing host cells to an increased amount of ALA effective to enhance or increase heme production in the host cell.
- the host cells can then be cultured to allow enhanced production of the target hemoprotein.
- the host cells can be exposed to enhanced amounts of ALA either endogenously or exogenously.
- ALA is added as a supplement to culture medium in which the host cells are grown as described in the Examples below.
- hemA refers to the gene
- HemA refers to the glutamyl tRNA (GTR) reductase.
- heterologous when referring to a gene, indicates that the gene has been inserted into a host cell that does not naturally carry the gene, either by way of a stable plasmid or through integration into the genome.
- protein when referring to a protein, indicates that the protein is the product of a heterologous gene.
- Heterologous proteins are proteins that are normally not produced by a host cell.
- the terms “enhanced” and “increased” are used interchangeably and mean a measurably greater amount of expression (i.e., overexpression) or production of a gene or target protein compared to the amount of expression or production of the same gene or protein prior to any manipulation of the host cell or culture medium.
- Recombinant systems for producing heterologous proteins or polypeptides, including hemoproteins are well known in the art.
- the genes encoding the target protein can be placed in a suitable expression vector and inserted into a microorganism, animal, plant, insect or other organism, or inserted into cultured animal or plant cells or tissues.
- These host cells, organisms or tissues may be produced using standard recombinant DNA techniques following the teachings of the present invention, and may be grown in cell culture or in fermentations.
- human alpha and beta globin genes have been cloned and sequenced by Liebhaver et al. fProc. Natl. Acad. Sci. USA. 77:7054-58, 1980) and Marotta et al. fj.
- Methods for incorporating the desired mutations are well known in the art and include, for example, site-directed mutagenesis. Random mutagenesis is also useful for generating a number of mutants at a particular site. Other recombinant techniques are also known, such as those described in U.S. Patent No. 5,028,588, U.S. Patent No. 5,545,727, U.S. Patent No. 5,599,907, PCT Publications WO 96/40920 and WO 97/04110, all incorporated herein by reference.
- the genes can be used to construct plasmids to be inserted into appropriate host cells according to conventional methods or as described in WO 96/40920, incorporated herein by reference.
- Any suitable host cell can be used to express the novel polypeptides.
- Suitable host cells include, for example, bacteria, yeast, plant, vertebrate and invertebrate animal cells, including mammalian and insect cells. Host cells in transgenic animals are also contemplated. E. coli cells are particularly useful for expressing desired recombinant hemoprotein.
- the transformed host cell is then cultured or fermented until soluble hemoglobin is harvested.
- the protein generally should be released from the cell to create a crude protein solution. This can usually be done by breaking open the cells, e.g., by sonication, homogenization, enzymatic lysis or any other cell breakage technique known in the art.
- the proteins can also be released from cells by dilution at a controlled rate with a hypotonic buffer so that some contamination with cellular components can be avoided (U.S. Patent No. 5,264,555).
- Cells also may be engineered to secrete the protein of interest by methods known in the art
- the target protein is contained in a crude cell lysate or crude cell broth or solution.
- the protein may be purified according to methods well known in the art. For example, methods for purifying hemoglobin-like proteins are taught in PCT publication WO 95/14038, incorporated herein by reference. The hemoproteins, so-produced, can be used for their known purposes.
- Heme- containing compounds known in the art include, for example, nitric oxide synthase, myoglobin, chlorophylls (from e.g., plants and bacteria), vitamin B12, catalase, siroheme, factor F430 and various hemoglobins, including those from human, yeast, bacteria, worms, crocodiles, and other sources.
- Heme-containing proteins for example the various types of hemoglobins, have many uses, including, for example, for delivery of oxygen or therapeutic uses.
- Other hemoproteins for example, P-450 enzymes which can be used for oxidation of drugs, alkaloids, terpenes, pesticides, carcinogens, and other xenobiotic chemicals are also important (Porter & Coo.
- Cytochrome P-450 enzymes can be used for detoxification of various chemicals.
- recombinant hemoglobin can be used for a number of in vitro or in vivo applications.
- in vitro applications include, for example, the delivery of oxygen by compositions of the instant invention for the enhancement of cell growth in cell culture by maintaining oxygen levels in vitro (DiSorbo and Reeves, PCT publication WO 94/22482, herein incorporated by reference).
- hemoglobins of the instant invention can be used to remove oxygen from solutions requiring the removal of oxygen (Bonaventura and Bonaventura, US Patent 4,343,715, incorporated herein by reference) and as reference standards for analytical assays and instrumentation (Chiang, US Patent 5,320,965, incorporated herein by reference) and other such in vitro applications known to those of skill in the art.
- recombinant hemoglobin can be formulated for use in various therapeutic applications.
- Example formulations suitable for the recombinant hemoglobin of the instant invention are described in Milne, et al., WO 95/14038 and Gerber et al., WO 96/27388, both herein incorporated by reference.
- Pharmaceutical compositions can be administered by, for example, subcutaneous, intravenous, or intramuscular injection, topical or oral administration, large volume parenteral solutions, aerosol, transdermal or mucus membrane adsorption and the like.
- the recombinant hemoglobins of the present invention can be used in compositions useful as tissue oxygenating therapeutics, as substitutes for red blood cells in any application that red blood cells are used or for any application in which oxygen delivery is desired.
- the recombinant hemoglobin formulated as oxygen therapeutics can be used for the treatment of hemorrhages, traumas and surgeries where blood volume is lost and either fluid volume or oxygen carrying capacity or both must be replaced.
- the recombinant hemoglobins of the instant invention can be made pharmaceutically acceptable, they can be used not only as blood substitutes that deliver oxygen but also as simple volume expanders that provide oncotic pressure due to the presence of the large hemoglobin protein molecule.
- the recombinant hemoglobins of the instant invention can be crosslinked by methods known in the art and used in situations where it is desirable to limit the extravasation or reduce the colloid osmotic pressure of the hemoglobin-based blood substitute.
- the recombinant hemoglobins can act to transport oxygen as a red blood cell substitute, while reducing the adverse effects that can be associated with excessive extravasation.
- a typical dose of recombinant hemoglobin as an oxygen delivery agent can be from 2 mg to 5 grams of hemoglobin per kilogram of patient body weight.
- a typical dose for a human patient might be from a few grams to over 350 grams.
- the unit content of active ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount could be reached by administration of a number of administrations. The selection of dosage depends upon the dosage form utilized, the condition being treated, and the particular purpose to be achieved according to the determination of those skilled in the art.
- Administration of recombinant hemoglobin can occur for a period of seconds to hours depending on the purpose of the hemoglobin usage.
- an oxygen carrier the usual time course of administration is as rapid as possible.
- Typical infusion rates for hemoglobin solutions as oxygen therapeutics can be from about 100 ml to 3000 ml/hour.
- the hemoglobins of the instant invention can be used to treat anemia, both by providing additional oxygen carrying capacity in a patient that is suffering from anemia, and/or by stimulating hematopoiesis as described in PCT publication WO 95/24213, incorporated herein by reference.
- the recombinant hemoglobins of the instant invention can be used for applications requiring administration to a patient of high volumes of hemoglobin as well as in situations where only a small volume of the hemoglobin of the instant invention is administered.
- the hemoglobins of the present invention can be used to deliver oxygen to areas that red blood cells cannot penetrate. These areas can include any tissue areas that are located downstream of obstructions to red blood cell flow, such as areas downstream of thrombi, sickle cell occlusions, arterial occlusions, angioplasty balloons, surgical instrumentation, any tissues that are suffering from oxygen starvation or are hypoxic, and the like. Additionally, all types of tissue ischemia can be treated using the hemoglobins of the instant invention.
- tissue ischemias include, for example, stroke, emerging stroke, transient ischemic attacks, myocardial stunning and hibernation, acute or unstable angina, emerging angina, infarct, and the like.
- Recombinant hemoglobin can also be used as an adjunct with radiation or chemotherapy for the treatment of cancer. Because of the broad distribution in the body, the recombinant hemoglobins of the instant invention can also be used to deliver drugs and for in vivo imaging as described in WO 93/08842, incorporated herein by reference.
- Recombinant hemoglobins can also be used as replacement for blood that is removed during surgical procedures where the patient's blood is removed and saved for reinfusion at the end of surgery or during recovery (acute normovolemic hemodilution or hemoaugmentation).
- the recombinant hemoglobins of the instant invention can be used to increase the amount of blood that can be predonated prior to surgery, by acting to replace some of the oxygen carrying capacity that is donated.
- the present invention further provides methods for enhancing the production of heme b . Such methods can be accomplished by inserting one or more copies of the hemA gene into a host cell capable of expressing heme b . The transformed host cell is then cultured to allow production and accumulation of heme,, Heme, usually in the form of heme-arginate as described in U.S. Patent No.
- 5,008,388 is a clinically important compound which is administered as treatment for hepatic porphyrias which result from a defect in the human heme synthetic pathway. It is also used to treat myelodysplastic syndrome and has potential for treatment of sickle cell disease, ⁇ - thalassemia, and prevention of myelosuppression associated with chemotherapy and AZT treatment (Mustajoki, Br. Med. J. 293:538-39 (1986); Volin, Leukemia Res. 12:423-31 (1988)). Therefore, heme and particularly heme-arginate can be used for hematopoiesis, myelodysplastic syndrome, porphyrias, as well as a natural coloring agent.
- ALA formation is a rate-limiting step in E.coli heme b biosynthesis, and that hemA, not hemM, encodes the major GTR reductase in the pathway.
- Three enzymes are necessary for conversion of glutamate to ALA by the C5 pathway (Fig. 1 ).
- GLTX and HemL are well known, the roles of HemA and HemM in the reaction catalyzed by GTR reductase are not.
- the hemA gene allowed an E.coli hemM mutant to form only small colonies on medium lacking ALA, and that hemM allowed that mutant to form large colonies, Ikemi et al.
- hemM encodes the major GTR reductase in E.coli, and that the GTR reductase encoded by hemA is involved in "an alternative minor pathway for ALA formation.” (Ikemi, et al., supra). The existence of two pathways for ALA formation is supported by the fact that there are two GTR reductase proteins in E.coli: a 45-kDa protein encoded by hemA, and an 85-kDa protein whose gene product has not yet been identified. Two facts suggest that hemM may not encode GTR reductase.
- the E.coli hemM protein encodes a 23-kDa protein in E.coli maxicells, and the deduced amino acid sequence of HemM bears no obvious homology to GTR reductase, or to any proteins whose functions have been described in Ikemi et al., supra.
- hemM encodes the predominant GTR reductase for the C5 pathway of ALA synthesis or that both hemA and hemM are required for maximal accumulation of ALA.
- a GTR reductase (hemA) mutant was not complemented with a plasmid containing hemM (pSGE1 104). ALA accumulation was enhanced when cells were provided with multiple copies of hemA, but not further enhanced when both hemA+M were provided.
- a wild-type strain containing this hemM-lacZ fusion produced 6118+ 492 Miller units of beta-gal actosidase activity, while a control strain, containing the pMLB1034 vector, produced less than one unit of activity.
- Both the hemM (pSGE1 104) and ⁇ e -4+M(pSGE1103) containing plasmids used herein contain the complete hemM coding sequence as well as 200 bp of upstream sequence.
- hemA and hemA RC Two different systems for increasing ALA pools— hemA and hemA RC — were evaluated in the present studies. Both systems allowed for an increase in cellular heme content, but the two systems had different effects on rHbl .1 accumulation.
- the strong tac promoter that drives the hemA RC gene in pSGEl 1 10 appears to be more efficient than either the hemA, or hemA 2 promoters, neither of which has ideal -10 or -35 consensus elements (Verkamp et al., 1989, supra.). While not wishing to be bound by any theory, it is possible that the level of HemA RC protein produced by pSGEl l lO is so high that the cell's capacity to produce rHbl.
- Bacterial strains and plasmids Bacterial strains and plasmids. Bacterial strains and plasmids used in this study are listed in Table 1.
- pSGE715 is a pUC-derived plasmid containing a synthetic, to -controlled operon composed of two genetically fused alpha subunits and one beta subunit of human hemoglobin and the lad gene for repression of the tac promoter as described in WO 97/04110.
- pSGE518 was derived from pRS415 (Simon et al., Gene.
- capsulatus hemA RC pSGE715 high copy plasmid for IPTG-con trolled expression of rHb 1.1 ; Tc pSGE494 pACYC184 with 1.2 kb Bamlll-Hindlll PCR fragment containing hemA pSGE862 pRS518 with 0.5 kb Hindlll-Bglll fragment of pSGE494 containing hemA) and hemA 2 promoters pSGE863 pRS518 containing 0.3 kb Hindlll-Bglll fragment containing hemA / promoter pSGE864 pRS518 containing 0.4 kb Hindlll-Bglll fragment containing hemA 2 promoter
- All PCR amplification reactions contained the following reagents: -100 ng of template DNA, 20-50 pmol of each primer, 20 mM Tris-HCl, 10 M KC 1 , 6 mM (NH 4 ) 2 SO 4 , 1.5 mM MgCl 2 , 0.1% Triton X-100, 0.2 mM of each of the four deoxyribonucleotide triphosphate
- All three hemA promoter fragments (Fig. 3) were amplified using the following cycle conditions (program "J"): one cycle of 5 min. at 95°C, 5 min. at 50°C, 1 min at 72°C; 28 cycles of 1 min. at 94°C, 1 min 50°C, and 30 sec. at 72°C; one cycle of 10 min. at 72°C.
- the hemA promoter fragment in pSGE863 (any other E. coli having a hemA promoter can be used) was amplified using primers EV50 and EV39.
- the hemA promoter fragment in pSGE864 (any E.
- coli having a hemA promoter was amplified using two sets of primers: EV45 an EV57, and EV53 and EV54.
- the use of two primer sets allowed removal of a small DNA segment containing the hemA, transcription start site described by Verkamp and Chelm (J. Bacteriol.. 171 :4728-4735 (1989)).
- the hemA gene fragment contained in pSGE494 (any other E. coli having a hemA gene fragment can be used) was amplified using program "J" and primers TG40 and TG41. The function of the hemA gene in pSGE494 was verified by complementation assay using an E. coli hemA mutant.
- a DNA fragment containing the coding sequence of hemA C was obtained by PCR using chromosomal DNA isolated from Rhodobacter strain SB 1003 (Hornberger, Mol. Gen- Genet. 221 :371-78 (1990); any other Rhodobacter strain containing the hemA RC promoter can be used), primers EV98 and EV99, and program "J" described above.
- Rhodobacter strain SB 1003 Rhodobacter strain SB 1003 (Hornberger, Mol. Gen- Genet. 221 :371-78 (1990); any other Rhodobacter strain containing the hemA RC promoter can be used
- primers EV98 and EV99 primers EV98 and EV99
- program "J" described above.
- Primers and cycle conditions used for amplification of the BamHI-HindlH fragment in pSGEl 104 were as follows: EV1 13 and TG224; one cycle of 5 min. at 95°C, 5 min. at 60°C, 3 min. at 72°C,
- Plasmid DNA for cloning and DNA sequencing was isolated using the Wizard plasmid isolation kit (Promega, Madison, WI) according to the manufacturer's instructions. Restriction digests, gel electrophoresis, DNA ligations and transformations were performed according to standard methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Springs Harbor, 1989). PCR fragments for ligation reactions were purified using a GENECLEAN II kit (Bio 101, Vista, CA). Both strands of DNA fragments generated by PCR were sequenced using the Prism DYE-terminator cycle sequencing system (Applied Biosystems, Foster City, CA) and an Applied Biosystems model 373 automated sequencer (Applied Biosystems, Foster City, CA). DNA sequences were analyzed using programs contained in the MacVector (version 4.5.2.) software package (International Biotechnologies, Inc. New Haven, CT).
- Beta-galactosidase assays Strains were grown overnight in 5 ml of M63 salts (Miller, Experiments in Molecular Genetics. (Cold Springs Harbor, 1972)) supplemented with 0.4% glucose, 0.1% casamino acids, 50 ⁇ g/ml proline, 40 ⁇ g/ml thiamine, 1 mM MgSO 4 , and appropriate antibiotics. Cells were diluted 1 :50 into test tubes containing 5 ml of the same medium, and grown at 37°C with shaking to OD ⁇ 0.4-0.8. Cultures were assayed for ⁇ - galactosidase according to the method described by Miller, supra.
- Fermentations were performed at 30°C in 15 liter fermentors (LSL Biolafitte, Inc.
- the seed inoculum for 15 liter fermentors was prepared in a two stage process.
- the primary seed stage was 500 ml of DM59 medium in a 2.5 liter shake flask inoculated with 0.5 ml of a stock culture preserved in 7% (v/v) dimethyl sulfoxide at ⁇ 80°C.
- the salts used in DM59 medium were as follows: 33 mM KH 2 PO 4 , 46 mM K 2 HPO 4 , 13 mM NaH 2 PO 4 , 18 mM Na-HPO 4 , 19 mM (NH 4 ) 2 SO 4 , 5.4 mM K 3 citrate, 2.2 mM Na 3 citrate, 4.2 mM MgSO 4 , 7.2 mM H 3 PO 4 .
- Trace metals were added to DM59 salts to the final concentrations indicated: 0.91 mM FeCl 3 , 0.14 mM ZnCl 2 , 12 ⁇ M CoCl 2 , 10 ⁇ M Na 2 Mo0 4 , 0.13 mM MnCl 2 , 0.41 mM CaCl 2 and 54 ⁇ M CuSO 4 .
- Glucose was added to a final concentration of 1% (w/v).
- Thiamine was added to a final concentration of 0.32 mg/ml.
- Antibiotics (see below) were added as needed to maintain plasmids. The primary seed stage . ,.
- the pH of the secondary seed stage culture was maintained at 20% in 2 liter fermentors.
- IPTG isopropyl B-D-thiogalactopyranside
- Heme b obtained as bovine hemin (Amesresco, Solon, OH), was dissolved in IN NaOH to a final concentration of 50 mg/ml. Where specified, heme b was added to fermentors at the time of IPTG induction, and at 3 and 6 hrs. post-induction, as 10 ml, 13 ml, and 17 ml aliquots.
- Antibiotics Sigma Chemical Co., St. Louis, MO were added to shake flasks and fermentors in the following concentrations: tetracycline, 15 ⁇ g/ml; chloramphenicol, 25 ⁇ g/ml, and ampicillin, 100 ⁇ g/ml.
- ALA and PBG assays One ml fermentation samples were resuspended in 10 mM
- MES pH 6.0
- Lysozyme, NaCl, and DNAse were added to final concentrations of 500 ⁇ g/ml (lysozyme), 100 mM (NaCl) and 60 ⁇ g/ml (DNAse), and samples were incubated on ice for 20 min., and then at 37°C for 2 min.
- Proteinase K Sigma Chemical Co., St. Louis, MO was added to a final concentration of 150 ⁇ g/ml, and samples were incubated for an additional 20 min. on ice. The sample pH was lowered to 5.5-5.9 by addition of 10% acetic acid.
- ALA and PBG were separated using a two-column chromatography system (ALA and PBG Column Test Kit) obtained from BioRad (Hercules, CA). ALA and PBG levels were quantified by their reactivity with Ehrlich's reagent, essentially as described in the BioRad test kit.
- Hemoglobin assay Samples (1 ml of fermentation broth at) were pelleted and resuspended in 25 mM Na ⁇ O ? . Lysozyme and NaCl were added to final concentrations of 1 mM NaCl and 0.75 mg/ml lysozyme, and the samples were incubated first at 4°C (30-40 min), and then at 37°C (3 min). DNAse (60 ⁇ g/ml) was added, and the samples were incubated 15 min. at room temperature. The samples were freeze-thawed, treated for 10 sec. with CO gas, and then diluted into a solution of 80 mM Tris-HCl, 2 M NaCl (pH8.0).
- the crude lysates were heated at 65°C for 4 min., and centrifuged at 13,000 x g for 2 min to remove cellular debris and contaminating proteins.
- the supernatant fraction containing partially purified hemoglobin was saved, and the hemoglobin was quantified by immobilized metal chelate chromatography using a Biocad Perfusion Chromatography Workstation (PerSeptive Biosystems, Cambridge, MA).
- the capture column was charged with a solution of 20 mM Zn(OAc) 2 , 200 mM NaCl, and equilibrated with 8 mM Tris-HCl, 200 mM NaCl (pH 8.0).
- Plasmid pSGE715 is a high-copy number plasmid for IPTG-controIled expression of the alpha and beta subunits of human hemoglobin. Following IPTG induction, E. coli strains containing pSGE715 produce large quantities of fully functional tetrameric hemoglobin variant (rHbl.l; WO 97/041 10). Because each hemoglobin tetramer has the capacity to bind four heme b groups, induction of rHbl.l is expected to rapidly deplete cellular pools of heme b . Accordingly, if heme b is a repressor of E.coli heme b synthesis, removal of heme b by rHbl .
- heme b is a negative regulator of the heme b pathway.
- shake flask cultures of SGE1453 Prior to induction of rHbl.l, shake flask cultures of SGE1453 contain approximately 25 pmoles/OD 600 *ml of heme b in heme b -containing proteins and as free heme b (Fig. 2, no ALA, zero hour time point).
- Fig. 2, no ALA, zero hour time point Prior to induction of rHbl.l, shake flask cultures of SGE1453 contain approximately 25 pmoles/OD 600 *ml of heme b in heme b -containing proteins and as free heme b (Fig. 2, no ALA, zero hour time point).
- Fig. 2, no ALA, zero hour time point Four hours following induction of rHbl . l, cultures of SGE1453 have approximately 75 pmoles/OD 600 *ml heme b (Fig. 2, no ALA, zero time point).
- This divergent transcript was shown to encode a 23-kDa protein, hemM, and a role for HemM in ALA synthesis was proposed (Chen et al., J. Bacteriol.. 176:2743-2746 (1994); Ikemi, supra.) .
- SGE1857 included the hemA l promoter
- SGE1858 included the hemA 2 promoter
- SGE1859 included both the hemA x and hemA 2 promoters.
- Beta- galactosidase activity assays indicated that both the hemA x and hemA 2 promoters are biologically active, and that the hemA, promoter is the stronger promoter (Table 2). Similar results were obtained when the three hemA-l ⁇ cZ fusions were integrated into the genome of a hemA mutant and grown with 0.2 ⁇ g/ml ALA.
- Cells were grown in five ml cultures and assayed as described in Materials and Methods. b Values reported are the average of four independent experiments. Variation is indicated in parentheses as standard error. A control strain containing pSGE518 produced 40
- heme b does not regulate hemA gene expression or the hemA promoters tested.
- ALA which is structurally similar to the dipeptide glycyl-glycine, is taken up by E.coli using a dipeptide permease. Because ALA is normally synthesized by E.coli cells rather than taken up by cells, transport of ALA by the dipeptide permease may be a relatively inefficient method for increasing intracellular ALA pools. Therefore, increasing ALA pools by genetically manipulating enzymes involved in ALA formation, especially GTR reductase, was examined to determine if they have a greater effect on cellular heme b content than supplementation with exogenous ALA. Accordingly, plasmids for overexpression of the hemA and hemM genes from their native promoters were constructed and evaluated in fermentation cultures (Table 3).
- Rhodobacter synthesize ALA by an alternate route, the C4 or Shemin pathway (Fig. 1).
- the C4 pathway requires only a single enzymatic step, and is catalyzed by the enzyme ALA synthase (E.C. 2.3.1.37)(Fig. 1).
- the Rhodobacter gene that encodes ALA synthase has been designated hemA. To avoid confusion with the E. coli hemA, which encodes a different activity, the Rhodobacter hemA gene is referred to herein as hemA RC .
- E.coli hemA mutants which require ALA supplementation for growth, can be complemented by the Rhodobacter / ⁇ em ⁇ fiC (Hornberger et al., Mol. Gen. Genet.. 221:371-378 (1990)).
- Rhodobacter / ⁇ em ⁇ fiC Rhodobacter / ⁇ em ⁇ fiC
- E.coli can produce heme b using enzymes from either the C4 or C5 pathways.
- hem RC was placed under control of the tac promoter to create an inducible system for studying the effect of high-level expression of ALA synthase on heme b pathway regulation.
- ALA and PBG pools in cells expressing hemA RC were significantly higher than in a control strain (SGE1453) following induction of HemA RC and rHbl . l expression (Tables 4 and 5). Although strains expressing HemA RC and rHbl. l (SGE2681) produced more heme b , the rates of rHbl. l accumulation for strains SGE1453 and SGE2681 were indistinguishable (Tables 4 and 5). The ratios of ALA and PBG in cells expressing hemA (SGE2644), hemA+M (SGE2658) and hemA RC (SGE2681) were considerably different.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41495/97A AU4149597A (en) | 1996-08-30 | 1997-08-29 | Production of heme and recombinant hemoproteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2581296P | 1996-08-30 | 1996-08-30 | |
US60/025,812 | 1996-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998008954A2 true WO1998008954A2 (fr) | 1998-03-05 |
WO1998008954A3 WO1998008954A3 (fr) | 1998-11-26 |
Family
ID=21828188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/014165 WO1998008954A2 (fr) | 1996-08-30 | 1997-08-29 | Production d'heme et d'hemoproteines de recombinaison |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4149597A (fr) |
WO (1) | WO1998008954A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018046512A1 (fr) * | 2016-09-08 | 2018-03-15 | Universitaet Bielefeld | Procédés et agents de production microbienne d'acide aminolévulinique |
WO2022269550A1 (fr) * | 2021-06-24 | 2022-12-29 | Reliance Industries Limited | Micro-organisme génétiquement modifié, procédé(s) et application(s) associés |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240831A (en) * | 1991-01-10 | 1993-08-31 | Board Of Regents, The University Of Texas | Methods and compositions for the expression of biologically active eukaryotic cytochrome p45os in bacteria |
US5635375A (en) * | 1995-01-09 | 1997-06-03 | Regents Of The University Of Colorado | Method of increasing the yield and heme saturation of cystathione β-synthase |
-
1997
- 1997-08-29 WO PCT/US1997/014165 patent/WO1998008954A2/fr active Application Filing
- 1997-08-29 AU AU41495/97A patent/AU4149597A/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018046512A1 (fr) * | 2016-09-08 | 2018-03-15 | Universitaet Bielefeld | Procédés et agents de production microbienne d'acide aminolévulinique |
WO2022269550A1 (fr) * | 2021-06-24 | 2022-12-29 | Reliance Industries Limited | Micro-organisme génétiquement modifié, procédé(s) et application(s) associés |
Also Published As
Publication number | Publication date |
---|---|
WO1998008954A3 (fr) | 1998-11-26 |
AU4149597A (en) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6136565A (en) | Methods of reducing the levels of protoporphyrin IX in recombinant hemoglobin preparations | |
JP4399634B2 (ja) | 増大した可溶性発現および/または低下した一酸化窒素の排出を伴うヘモグロビン変異体 | |
Frey et al. | Bacterial hemoglobins and flavohemoglobins: versatile proteins and their impact on microbiology and biotechnology | |
Verderber et al. | Role of the hemA gene product and delta-aminolevulinic acid in regulation of Escherichia coli heme synthesis | |
US5840851A (en) | Purification of hemoglobin | |
EP0625202B1 (fr) | Serum-albumine humaine, preparation et utilisation | |
US7410788B2 (en) | Compositions and methods for production of disulfide bond containing proteins in host cells | |
CA1339299C (fr) | Adn codant la superoxydase-dismutase de manganese humaine; son expression; methode pour la recuperer; analogues ou mutants de superoxydase-dismutase de manganese humaine; utilisations, compositions et methodes de traitement | |
CA2446010A1 (fr) | Production de lantibiotique | |
WO2004001048A1 (fr) | Composition pharmaceutique et methode de traitement de malignites humaines par reduction du niveau d'arginine | |
JP2010011852A (ja) | 細菌フェロモンおよびその使用 | |
WO2007127735A2 (fr) | Cellules hôtes procaryotes destinées à exprimer des protéines riches en liaisons disulfure | |
EP0483113B1 (fr) | Méthode de production d'un analogue de Cu/Zn SOD humain enzymatiquement actif | |
EP0832228B1 (fr) | Composes modifies analogues a l'hemoglobine et leurs procedes de purification | |
WO1998008954A2 (fr) | Production d'heme et d'hemoproteines de recombinaison | |
US10752672B1 (en) | Recombinant hemoglobins and methods of preparation and use thereof | |
US6171826B1 (en) | Methods of controlling beta dimer formation in hemoglobin | |
US20040161809A1 (en) | Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents | |
EP1950298A2 (fr) | Mutants d'hémoglobine dotés d'une expression soluble accrue et/ou d'une évacuation réduite de l'oxyde nitrique | |
Cardin et al. | Isolation of a Rhodobacter capsulatus bioB mutant and cloning of the bioB gene | |
CA2618690A1 (fr) | Mutants d'hemoglobine avec expression soluble accrue et/ou evacuation reduite d'oxyde nitrique | |
WO1999045123A1 (fr) | Reductase de la thioredoxine du staphylocoque obtenue par recombinaison, et certains de ces inhibiteurs convenant comme agents antimicrobiens | |
AU2478295A (en) | Purification of hemoglobin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998511685 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |